Lilly is picked for the FDA's PreCheck manufacturing pilot

The Food and Drug Administration has selected Eli Lilly and six other companies for a pilot program called PreCheck, designed to speed up regulatory review of new U.S. drug manufacturing plants.^[1] The agency announced the seven participants on June 29, and Lilly's site is a facility in Lebanon, Indiana, that will make active pharmaceutical ingredients, or APIs, for the company's current and future medicines.^[1]

PreCheck grew out of a May 2025 presidential order directing the FDA and other federal agencies to reduce regulatory barriers to domestic drug production.^[1] The FDA proposed the program later that year, offering companies technical guidance and facility-focused meetings with regulators before formal applications are filed.^[1] Some industry executives called the original proposal a welcome but incomplete step when it was discussed at a meeting in October.^[1] The agency finalized the program and set a February 1 launch date for the pilot earlier this year.^[1]

Alongside Lilly, the FDA selected Amneal Pharmaceutical, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, Kyowa Kirin and Regeneron Pharmaceuticals.^[1] Each company's participation is tied to one specific facility. Regeneron's site is a planned $2 billion, one-million-square-foot plant in Saratoga Springs, New York, meant to more than double the company's manufacturing capacity in the state.^[1] Fujifilm's site is a large-scale cell culture plant in Holly Springs, North Carolina, which is also linked to separate manufacturing deals with Regeneron and Johnson & Johnson.^[1] North Carolina hosts three of the seven pilot facilities in total, including sites run by Kriya Therapeutics and Kyowa Kirin.^[1]

Lilly's Lebanon, Indiana, project is part of a broader $4.5 billion commitment the company made to two sites in that town, one of which is focused specifically on producing APIs for its obesity medicines.^[1] The source does not specify which of Lilly's obesity products, such as tirzepatide (marketed as Mounjaro and Zepbound), would draw on this ingredient supply, and it does not give a timeline for when the Lebanon plant will be operational or how many total sites Lilly is building nationwide.^[1]

Why it matters for patients

Supply shortages of GLP-1 drugs have been a recurring problem for patients trying to fill prescriptions for weight loss or diabetes treatment. A federal push to speed up new domestic manufacturing plants, and the inclusion of a facility tied to obesity-drug ingredients, points toward efforts to shore up the supply chain behind these medicines.^[1] However, the source does not say when the Lebanon plant will begin producing ingredients or how quickly any added capacity might translate into more product on pharmacy shelves. Patients should not expect an immediate change in availability or pricing from this announcement alone, since PreCheck affects how the FDA reviews new facilities, not the medicines already on the market.^[1]

Not every company that wanted into the program was chosen. Denali Therapeutics said it had hoped to join PreCheck to work with the FDA on a facility for an experimental treatment, and its CEO said manufacturing capacity for that product remains a bottleneck.^[1] This suggests that even among drugmakers eager for regulatory support, program slots were limited to seven sites in this pilot round.^[1]

What happens next

The source does not lay out further dated milestones beyond the June 29 selection of participants and the program's earlier February 1 pilot launch.^[1] It is not yet known from available reporting when Lilly's Lebanon, Indiana, facility will be completed or when it will begin supplying ingredients for obesity medicines.^[1]